Gastroparesis Registry

The purpose of the national Gastroparesis Registry is to better understand gastroparesis by following and periodically evaluating people with this condition. The data collected through this research study will improve the diagnosis and treatment of patients with gastroparesis. The Gastroparesis Registry is an observational study. Treatment for gastroparesis will not be provided by this study. This study is a nationwide study funded by the NIH. Participation could last up to 4 years.

Eligibility:

Age: 18 years and older

Gender: Male and female

Ethnicity: All

Race: All

Smoking: Smoking and nonsmoking volunteers

Medication: No restriction

Study population: patients with symptoms of gastroparesis

Other Eligibility Factors

• Must have a delayed gastric emptying and/or symptoms of gastroparesis within the last 6 months.
• Must have had an upper endoscopy within the past 12 months.
• Nausea, vomiting, early satiety (a sense that you cannot finish a mormal-sized meal), fullness after eating, and abdominal pain associated with gastroparesis.

Location of Study Visits

• Ann Arbor

Prinicipal Investigator:

• William L Hasler, MD

Contact:

• Michelle Atkinson 734-615-6723 or e-mail: michcast@umich.edu
  

This clinical study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). For more information provided by NIDDK, click on the link to the Nortriptyline for Idiopathic Gastroparesis study at the following web address: http://www.clinicaltrials.gov/ct2/show/NCT00765895?term=gastroparesis&rank=9

Nortiptyline for idiopathic gastroparesis: a multicenter, randomized, double-masked, placebo-controlled trial

The purpose of this study is to find out whether treatment with the medication nortriptyline is better than a placebo in improving the symptoms of patients with gastroparesis &ndash specifically, the type of gastropareisis called "idiopathic", which means "of unknown cause or origin." Nortriptyline is approved by the United States Food and Drug Administration for treatment of depression. It is not currently approved for symptoms of gastroparesis.

Eligibility

Age Range: From 25 to 65 years

Gender: Male & female

Ethnicity: All

Race: All

Smoking: Both smoking and nonsmoking volunteers

Medication: Not taking medication

Study population: patients with symptoms of gastroparesis

Other Eligibility Factors

• Documentation of delayed gastric emptying within 2 years.
• Negative upper endoscopy or upper GI series within 2 years of registration date.
• Symptoms of gastroparesis for at least 6 months (does not have to be contiguous

Prinicipal Investigator:

• William L Hasler, MD

Contact:

• Michelle Atkinson 734-615-6723 or e-mail: michcast@umich.edu

This clinical study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). For more information provided by NIDDK, click on the link to the Gastroparesis Registry study at the following web address: http://www.clinicaltrials.gov/ct2/show/NCT00398801?term=gastroparesis&rank=5